UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5748-5754

2008

Volltextzugriff (PDF)

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Journal of clinical oncology, 2018-02, Vol.36 (4), p.391-398

2018

Volltextzugriff (PDF)

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Journal of clinical oncology, 2008-05, Vol.26 (14), p.2292-2298

2008

Volltextzugriff (PDF)

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Cancer immunology research, 2014-07, Vol.2 (7), p.632-642

2014

Volltextzugriff (PDF)

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Clinical cancer research, 2007-04, Vol.13 (7), p.2100-2108

2007

Volltextzugriff (PDF)

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group

Journal of clinical oncology, 2014-11, Vol.32 (33), p.3771-3778

2014

Volltextzugriff (PDF)

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Clinical cancer research, 2017-09, Vol.23 (17), p.5034-5043

2017

Volltextzugriff (PDF)

Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma

Journal of clinical oncology, 2009-12, Vol.27 (36), p.6207-6212

2009

Volltextzugriff (PDF)

Multicenter phase ii trial of high-dose imatinib mesylate in metastatic melanoma : Significant toxicity with no clinical efficacy

Cancer, 2006-05, Vol.106 (9), p.2005-2011

2006

Volltextzugriff (PDF)

Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

Clinical cancer research, 2007-04, Vol.13 (7), p.2115-2120

2007

Volltextzugriff (PDF)

Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital

World journal of gastroenterology : WJG, 2015-04, Vol.21 (14), p.4373-4378

2015

Volltextzugriff (PDF)

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Clinical cancer research, 2007-06, Vol.13 (11), p.3312-3319

2007

Volltextzugriff (PDF)

Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1196-1202

2010

Volltextzugriff (PDF)

A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma

Cancer, 2010-04, Vol.116 (7), p.1751-1756

2010

Volltextzugriff (PDF)

Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma

Clinical cancer research, 2010-04, Vol.16 (8), p.2402-2408

2010

Volltextzugriff (PDF)

Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-γ Induction Is Associated with Clinical Response

Clinical cancer research, 2000-05, Vol.6 (5), p.1678

2000

Volltextzugriff (PDF)

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

Cancer medicine (Malden, MA), 2017-08, Vol.6 (8), p.1904-1914

2017

Volltextzugriff (PDF)

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

The oncologist (Dayton, Ohio), 2015-06, Vol.20 (6), p.617-618

2015

Volltextzugriff (PDF)

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma

Clinical cancer research, 2002-10, Vol.8 (10), p.3075

2002

Volltextzugriff (PDF)

Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687)

Anti-cancer drugs, 1999-02, Vol.10 (2), p.245-248

1999

Volltextzugriff (PDF)

A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor

Clinical cancer research, 1998-05, Vol.4 (5), p.1203-1213

1998

Volltextzugriff (PDF)

Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study

Journal of clinical oncology, 2004-06, Vol.22 (11), p.2101-2107

2004

Volltextzugriff (PDF)

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

Melanoma research, 2021-02, Vol.31 (1), p.67-75

2021

Volltextzugriff (PDF)

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells

Journal of clinical oncology, 1990-07, Vol.8 (7), p.1138-1147

1990

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

KollektionAUTh Library subscriptions: Taylor & Francis Journals

KollektionApplied Social Sciences Index & Abstracts (ASSIA)

ThemaImmunotherapy

ThemaAged

ThemaFemale

ThemaMelanoma - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(25)

Sprache

Englisch
(25)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study

Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer

Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697)

Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma

Multicenter phase ii trial of high-dose imatinib mesylate in metastatic melanoma : Significant toxicity with no clinical efficacy

Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697)

Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak

Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

Cytokine Working Group Study of Lymphodepleting Chemotherapy, Interleukin-2, and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma: Clinical Outcomes and Peripheral-Blood Cell Recovery

A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma

Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma

Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-γ Induction Is Associated with Clinical Response

A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status

A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma

Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687)

A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor

Temozolomide for the Treatment of Brain Metastases Associated With Metastatic Melanoma: A Phase II Study

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells

Aktive Filter

Suchergebnisse filtern